Welcome to our dedicated page for PFIZER SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PFIZER's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PFIZER's regulatory disclosures and financial reporting.
Quincey James reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director James Quincey received a grant of phantom stock units as deferred board compensation. On March 27, 2026, he was awarded 1,433.062 Phantom Stock Units, each linked to one share of Pfizer common stock and valued at $27.04 per unit. Following this award, his reported balance rose to 77,317.538 phantom units. These units represent deferred director compensation, including dividend equivalents, and will be settled in cash or common stock at his election after he retires from the Board.
NARAYEN SHANTANU reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Shantanu Narayen received a compensation grant of 1,849.112 Phantom Stock Units tied to Pfizer common stock. The units were credited at a reference price of $27.04 per unit and increase his phantom stock balance to 187,925.141 units.
Each unit represents one phantom share of common stock and forms part of deferred director compensation, including dividend equivalents. According to the disclosure, these units will be settled in cash or Pfizer common stock, at the director's election, after he retires from the Board.
Echevarria Joseph reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Joseph Echevarria received a grant of 1,710.429 Phantom Stock Units tied to Pfizer common stock. Each unit represents one phantom share of common stock and was valued at $27.04 per unit on the grant date. After this award, his reported phantom unit balance increased to 153,398.145 units. These units represent deferred director compensation, including dividend equivalents, and will be settled in cash or Pfizer common stock at his election after he retires from the Board of Directors.
Buckley Mortimer J reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director Mortimer J. Buckley received a grant of 1,386.834 Phantom Stock Units on deferred compensation terms. Each unit represents one phantom share of common stock valued at $27.04. Following the award, Buckley holds 16,704.585 Phantom Stock Units, which will be settled in cash or stock after his retirement from the Board.
Pfizer Inc. ownership filing: The Vanguard Group filed an amendment reporting 0 shares of Pfizer common stock, representing 0% of the class. The filing states that on January 12, 2026 Vanguard completed an internal realignment and now reports beneficial ownership of certain subsidiaries separately in reliance on SEC Release No. 34-39538 (January 12, 1998).
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. It lists Vanguard's address as 100 Vanguard Blvd., Malvern, PA and reiterates that no single outside person holds more than 5% of the class according to the disclosure.
Pfizer Inc. reported that Chairman and CEO Albert Bourla acquired 1,630 phantom stock units linked to Pfizer common stock. The units were granted at a reference price of $26.58 per unit under the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan.
Each unit tracks one share of common stock but is settled in cash after his separation from service rather than in actual shares. Following this grant, Bourla holds a total of 759,400 phantom stock units, providing cash-based exposure to Pfizer’s share value as part of his long-term compensation.
Pfizer Inc. is asking shareholders at its virtual April 23, 2026 annual meeting to elect 12 directors, ratify KPMG as auditor, approve the amended 2019 Stock Plan, hold an advisory vote on executive pay and consider a shareholder proposal for an independent chair.
The proxy highlights 2025 results: total revenue of $62.6 billion versus $63.6 billion with a 2% operational decline, but 6% operational growth excluding COVID-19 products. Pfizer advanced a 102-project R&D pipeline and completed strategic deals including the Metsera acquisition and licensing agreements with 3SBio and YaoPharma.
Cost realignment is expected to deliver about $5.7 billion in net savings by 2026, plus roughly $1.5 billion from manufacturing optimization by 2027. In 2025 the company returned $9.8 billion in cash dividends, invested $10.4 billion in internal R&D and about $8.8 billion in business development, while maintaining a long dividend record and emphasizing board independence and risk oversight.
Pfizer Inc. senior vice president and controller Jennifer B. Damico reported equity compensation activity and related tax withholding. On March 3, she received grants of Pfizer common stock totaling 21,719 shares in the form of restricted stock units, which are subject to vesting requirements, and 22,638 stock appreciation rights that will be settled in common shares on the fifth anniversary of the grant date.
On March 4, 826 shares of common stock were withheld to cover tax obligations when restricted stock units (and related dividend equivalents) vested. After these transactions, she directly held 32,934 Pfizer common shares.
Pfizer Inc. reported that Chairman and CEO Albert Bourla received a grant of 708,666 stock appreciation rights on March 3, 2026. These rights were acquired as a grant or award, not through open-market purchases.
According to the disclosure, the stock appreciation rights are subject to vesting conditions and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date. After this transaction, Bourla held a total of 708,666 stock appreciation rights directly.